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Myasthenia gravis (MG) is a rare autoimmune disease in which antibodies bind to acetylcholine 
receptors in the postsynaptic membrane at the neuromuscular junction. Muscle-specific kinase 
(MuSK) antibody-associated MG patients often have severe symptoms, including bulbar 
dysfunction, respiratory insufficiency and atrophy of the facial and tongue muscles. Fluctuating 
character and the similarity of symptoms to those of other disorders make MG one of the most 
challenging medical diagnoses. Initial misdiagnosis of MuSK-MG can lead to worsening of 
symptoms. The diagnosis is confirmed by positive results on pharmacological testing, 
electrodiagnostic testing and serum antibody assay. Symptomatic, immunoactive, and 
supportive approaches to therapy have very good effect and the prognosis is improved with 
precocious interventions.  
 




A miastenia gravis (MG) é uma doença autoimune rara na qual os anticorpos se ligam aos 
receptores de acetilcolina na membrana pós-sináptica da junção neuromuscular. Pacientes com 
MG associado ao anticorpo músculo quinase específico (MuSK) freqüentemente apresentam 
sintomas graves, incluindo disfunção bulbar, insuficiência respiratória e atrofia dos músculos 
faciais e da língua. O caráter flutuante e a semelhança dos sintomas com os de outras doenças 
tornam a MG um dos diagnósticos médicos mais desafiadores. O diagnóstico incorreto de 
MuSK-MG pode levar ao agravamento dos sintomas. O diagnóstico é confirmado por 
resultados positivos em testes farmacológicos, testes de eletrodiagnóstico e análise de 
anticorpos séricos. As abordagens sintomáticas, imunoativas e terapias de supeorte têm um 
efeito positivo na sintomatologia e o prognóstico é melhorado com intervenções precoces.  
 




Myasthenia gravis (MG) is an autoimmune disorder in which muscle weakness occurs 
as a result of impairment of neuromuscular transmission (CARR et al, 2010). The knowledge 
on myasthenia gravis pathogenesis has greatly increased, and it is now recognized to have wide 
clinical phenotypes based on the presence of the different autoantibodies (MANTEGAZZA et 
al, 2018). MG is caused by autoantibodies that target the postsynaptic membranes of 
neuromuscular junctions (NMJs), cholinergic synapses that connect nerve terminals and 
skeletal muscle fibers (MORI et al, 2013).  
In Brazil the incidence of MG varies from 1 to 9 per million inhabitants (MINISTÉRIO 
DA SAÙDE, 2015). Symptoms are characterized by fluctuating weakness that improves with 
rest and worsens with exercise, infections, menstruation, anxiety, emotional stress and 
pregnancy. Weakness can be limited to specific muscle groups (ocular, facial, bulbar muscles) 
or be generalized (GILHUS, 2016).  
These antibodies can be divided in three different classes: antibodies against 
acetylcholine receptors (AChR), muscle-specific kinase (MuSK) and lipoprotein receptor-
related protein 4 (LRP4) (GILHUS, 2016). The majority of abs positive myastehnic patients 
have AChR antibodies, with an initial ocular symptomatology converging to a generalized form 
within one year and good resposnse to acetylcholinesterase inhibitors (AChE-I) 
(MANTEGAZZA et al, 2018).. Approximately 5-8% of the total number of patients with 
myasthenia gravis (MG) has antibodies against the muscle specific tyrosine kinase (MuSK) 
receptor. These patients exhibit a distinct clinical phenotype and may differ from “typical” MG 
associated with antibodies against the acetylcholine receptor (AChR) (FURUTA et al, 2015). 
MG associated with MuSK antibodies has some distinct clinical features, including prevalent 
involvement of cranial and bulbar muscles and frequent intolerance of (AChE-I). Cramps and 
fasciculations may also occur in patients with MG following treatment with AChE-I, 
particularly in patients with MuSK-MG (SIMON et al, 2013). 
MG remains one of the most challenging medical diagnoses due to its fluctuating 
character and to the similarity of its symptoms to those of other disorders (JUEL et al, 2007). 
The initial clinical course might be interpreted as fatigue, tiredness or laziness. So, the 
complication with respiratory insufficiency may lack a previous clinical history that would help 
with the diagnosis. We would like to present a case that exemplify these “false” acute 








A 45-year-old woman went to the general physician complaining of dyspnea, she was 
no longer able to perform her dance classes. She had an unremarkable spirometry and showed 
night desaturation in the polysomnography. She started domiciliary oxygen at night and was 
referred to a pneumologist. 
 Before the consultation, she had an acute episode of ventilatory insufficiency associated 
with a decrease in consciousness level (gasometer analysis: SpO2: 92%, PCO2: 90mmHg, 
PaO2: 72.2 mmHg). She went to the emergency room and was submitted to mechanical 
ventilation. Pulmonary thromboembolism was ruled out after angiotomography. The 
tomography revealed a pneumonic infiltration, she was treated with antibiotics. A 
bronchospasm therapy with use of venous hydrocortisone was added after the evidence of 
wheezing on auscultation. She got better after the whole treatment without oxygen dependence 
and went back home. The medical team listened to her family that reported she was feeling 
weak for about one year and was also sadder since her husband was diagnosed with cancer, 
always with an unhappy face. So, it was suggested that her respiratory failure was secondary to 
a psychogenic disorder and she was referred to the psychiatry. Two weeks later, she started to 
feel the same symptoms again, and needed to use night oxygen. 
 She has referred to our team at the occasion. The first examination showed a restricted 
gaze upwards and restricted adduction on the bilateral gaze with a bilateral ptosis with no 
fluctuation during the day. The palate elevation and nausea reflex were impaired, with an 
inefficient swallow. Global force, sensibility, coordination and tendon reflexes were preserved.  
The gasometer showed high CO2 pressure (60 – 70 mmHg), her spirometry showed a restrictive 
and obstructive pattern and the manovacuometry was normal. The electromyography showed 
no alterations even after the repetitive stimulation. The ice test was negative, the pyridostigmine 
test showed a slightly improvement of the upward gaze and lateral gaze. The laboratory exams 
revealed normal thyroid, liver and kidney function, normal creatine phosphokinase (cpk) (91 
U/L) and lactate (0,2 – 2,4 mg/dL ) value. We ordered the anti-acetylcholine dosage and decided 
to use the pyridostigmine for a myasthenia therapeutic test. 
 On the next day, she presented a tongue fasciculation. There was no improvement with 
pyridostigmine and the anti-acetylcholine was negative. The ventilatory function was getting 
worst. Therefore, we decided to ask for an anti-musk dosage and tried an empirical treatment 
with immunoglobulin (there were no availability of plasmapheresis – our first option). After, 
2g/kg of immunoglobulin she presented no improvement. 
 The dosage of anti-musk was positive and we started prednisone – 1mg/Kg. She 
continued with BIPAP, showed an initial decline in the ventilatory function followed by an 
improvement. Nowadays she is using azathioprine, gradually tapping  the prednisone and need 




 In this report, we described a case of a patient with myasthenia gravis MuSK positive 
with missed signs of her clinical presentation and a misdiagnosis. Some important clinical 
aspects regarding her case will be discussed in order to focus the relevant signs and symptoms 
to guide a diagnosis of myasthenia.  
The clinical presentation of MuSK-MG patients can be atypical and symptom 
fluctuation, which is a clinical hallmark of MG, can be minimal or absent (EVOLI et al, 2013). 
Respiratory muscle weakness can occur in up to 40% of MG patients leading to dyspnea or 
orthopnea. Roughly 15% to 20% of patients with MG will experience myasthenic crisis, defined 
as respiratory failure necessitating either noninvasive positive pressure ventilation or 
mechanical ventilation until clinical improvement occurs. Respiratory muscle weakness is 
typically associated with concurrent bulbar and neck muscle weakness and more predominant 
in MuSK + patients (HEHIR et al, 2018) (MORI et al, 2013) (EVOLI et al, 2012), as showed 
by our patient. 
Patients with both defined and undiagnosed neuromuscular disorders are frequently 
admitted to hospital services and clinicians must be able to recognize and intervene 
appropriately when respiratory failure develops. Early recognition of acute neuromuscular 
respiratory failure (NRF) and determination of the cause is imperative, as there are survival 
implications (HOCKER, 2017). 
In general, failure of the lung caused by a variety of lung diseases (e.g. pneumonia, 
emphysema and interstitial lung disease) leads to hypoxaemia with normocapnia or hypocapnia 
(hypoxaemic or type I respiratory failure). Failure of the pump (e.g. drug overdose) results in 
alveolar hypoventilation and hypercapnia (hypercapnic or type II respiratory failure). Although 
there is coexistent hypoxaemia, the hallmark of ventilatory failure is the increase in PCO2 
(ROUSSOS et al, 2003). 
When the diaphragm and intercostal muscles become sufficiently weak that they cannot 
lift the ribcage, accessory muscles attached to the ribcage are enlisted to move it and assist with 
ventilation. These compensatory mechanisms provide only partial compensation, resulting in 
microatelectasis at the lung bases. At this stage, the patient may be tachypneic and examination 
of the arterial blood gas (ABG) will show a respiratory alkalosis with normal or mildly reduced 
PO2. As the muscles fatigue, generalized hypoventilation develops. The patient compensates 
by increasing their respiratory rate further (rapid shallow breathing) and thus testing of the 
blood gas at this stage will reveal a normal PCO2. Further muscular fatigue leads eventually to 
hypercapnia and respiratory acidosis (HOCKER, 2017). Mechanical defects of the chest wall 
(flail chest and acute hyperinflation), neuromuscular diseases (bilateral diaphragmatic 
paralysis, myasthenia Gravis, botulism and Guillain-Barre´ syndrome) and pharmacological 
agents such as curare may result in acute hypercapnia (ROUSSOS et al, 2003). 
A diurnal fluctuation of myasthenic symptoms may not be evident in some patients. The 
often negative edrophonium test and/or negative repetitive nerve stimulation study may make 
the MuSK-MG diagnosis less obvious. It is important to differentiate MuSK-MG from 
amynotrophic lateral sclerosis (ALS), since both can present tongue atrophy and fasciculation 
as reported in the case. In MuSK-MG upper motor neuron dysfunction is usually absent, 
creatine kinase level is typically normal and the denervation is rarely seen on needle 
electromyography (MORREN et al, 2018). 
Moreover, it is important to emphasize the possible co-existance of myasthenia and 
depression, that is present in our case. Since the fatigability present in myasthenic patients can 
resemble a sad face or apathy, it is always important to evaluate if the depression really explain 
all the symptoms of the patient. 
For cost effectiveness, MuSK-Ab testing should be reserved for patients who have tested 
seronegative for AChR-Abs or patients who have tested positive for AChR-Ab but respond 
poorly to treatment (MORREN et al, 2018). Therefore, only the anti-acetylcholine dosage were 
ordered initially and the MuSK dosage was reserved for after the poor response to the 
convetional treatment 
Therapeutic management of MG is based on the use, most often in combination, of 
acetylcholinesterase inhibitors (AChE-I) as symptomatic medication, thymectomy, 
pharmacological immunosuppression, and short-term immunomodulation with plasma-
exchange and intravenous immunoglobulin (IVIg). Pyridostigmine is the AChE-I agent most 
commonly used, is generally well tolerated and represents the first-line treatment in MG, 
(HEHIR et al, 2018). Thymectomy is indicated in all patients with thymoma to treat a 
potentially malignant tumor; moreover, it is currently performed in generalized AChR-MG , it 
appears to increase the likelihood of medication free remission and reduce the patients 
hospitalization (WOLFE et al, 2016, 2019). Several lines of evidence suggest that thymectomy 
may not be beneficial for MuSK-MG. The MuSK-Ab level remains unchanged after 
thymectomy in contrast to its reduction after successful immunosuppression. Histological 
findings of the thymus gland removed from patients with MuSK-MG were often normal for age 
or atrophic (REDDEL et al, 2014). Thymus alteration appear to be definitely uncommon in 
MuSK-MG, supporting the view that the thymus does not play a pathogenic role in this form 
of MG (EVOLI et al, 2013).  
Immunosuppressive treatment reduces the level of pathogenic antibodies through 
different effects on immune system and is performed in patients with disabling symptoms, not 
satisfactorily controlled with AChE-Is. It includes corticosteroids, alone or in combination with 
a variety of drugs as antimetabolites (azathioprine, mycophenolate mofetil), calcineurine 
inhibitors (cyclosporine, tacrolimus), alkilating agents (cyclophosphamide) and rituximab 
(SANDERS et al, 2016). Plasma exchange removes antibodies and cytokines from circulation, 
while IVIg has complex effects on the immune system mostly mediated through interference 
with idiotype network and modulation of T and B cell activation. Both plasma-exchange and 
IVIg induce rapid, though short-term improvement, and are mainly employed in association 
with pharmacological immunosuppression, in treating disease exacerbation phases and in 
preparation for thymectomy (EVOLI et al, 2013). 
Regarding our case, the next day after starting the pyridostigmine the patient showed no 
improvement and presented a tongue fasciculation together with ventilatory function 
deterioration. In MuSK-MG animal models, clinically appropriate doses of pyridostigmine 
exacerbated weakness, end plate AChR loss and impaired end plate electrophysiological 
measures in the diaphragm muscle. Hypersensitivity to ACEI merits extra caution when treating 
patients with MuSK-MG who are at risk for myasthenic crisis because increased bronchial and 
oropharyngeal secretions could further aggravate impaired breathing and/or swallowing 
(MORREN et al, 2018).  
Immunosuppression is the mainstay treatment in all forms of MG. This is particularly 
true in MuSK-MG, where weakness severity and poor response to AChE-Is imply prompt and 
aggressive treatment (EVOLI et al, 2012).Currently, the 3 most effective treatments for MuSK 
MG are corticosteroids, plasmapheresis, and rituximab (MORREN et al, 2018).There is a 
general agreement that MuSK-MG responds well to steroids and dramatically to plasma-
exchange. The association of high-dose prednisone (1 to 1.5 mg/kg body weight/day) and 
plasma-exchange (five exchanges of 40 to 50 ml/body weight each on alternate days) is the 
treatment of choice in patients with respiratory crisis or severe bulbar weakness, as in other 
forms of MG (EVOLI et al, 2013). 
 However, after the positive dosage of anti-MuSK ab the patient showed no improvement 
with the use of immunoglobulin and we had to start the prednisone. Her ventilatory function 
has improved and the oxygen supplementation is no longer needed. Response to corticosteroids 
is relatively fast, usually within 2–3 weeks. Because of the rapid onset of action, corticosteroids 
are often the first line immunotherapy for MuSK-MG. However, the maintenance corticosteroid 




The early diagnosis of acute neuromuscular respiratory failure and the determination of 
the cause are extremely relevant, because they can interfere on the patients' survival and 
comorbidities. Neuromuscular diseases should be always investigated in type II respiratory 
failure, considering that the determination of the cause required strenuous investigation, 
alternated with empirical attempts at treatment, demonstrating the importance of recognizing 
the possible differential diagnoses for controlling the disease course. 
Myasthenia gravis remains a challenging diagnosis for doctors, since it has different 
spectra of clinical manifestations, in addition to a fluctuating course and characteristics similar 
to other diseases, which makes it even more relevant to raise it as a diagnostic hypothesis by 
attending physicians. 
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